[186Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model

Anuradha Soundararajan, Ande Bao, William T Phillips, Ricardo Perez, Beth A. Goins

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The purpose of this study was to determine the feasibility of radiolabeling liposomal doxorubicin (Doxil) for cancer chemoradionuclide therapy by directly loading the therapeutic radionuclide rhenium-186 (186Re) into the liposome interior. The pharmacokinetics, imaging and biodistribution of [186Re]Doxil (555 MBq/kg) and control [186Re]polyethylene glycol (PEG) liposomes (555 MBq/kg) were determined after intravenous administration in a head and neck cancer xenograft model in nude rats. [186Re]Doxil and [186Re]PEG liposomes were radiolabeled using [186Re]N,N-bis(2-mercaptoethyl)-N′,N′-diethylethylenediamine. 186Re labeling efficiency was 76.1±8.3% with Doxil. The in vitro serum stability of [186Re]Doxil at 37°C was 38.06±12.13% at 24 h. Pharmacokinetic studies revealed that [186Re]Doxil had a two-phase blood clearance with half clearance times of 0.8 and 28.2 h. Images acquired over 120 h showed that [186Re]Doxil had slow blood clearance, low liver accumulation and increasing spleen accumulation. The biodistribution study at 120 h indicated that the percentage of injected dose (%ID) in the blood and tumor for [186Re]Doxil was 20-fold higher than that of [186Re]PEG liposomes. The %ID values in the kidney and liver were not significantly different between [186Re]Doxil and [186Re]PEG liposomes. These results suggest that the long circulation and prolonged bioavailability of [186Re]Doxil could potentially deliver high concentrations of both doxorubicin and 186Re to tumor when encapsulated in the same liposome vehicle.

Original languageEnglish (US)
Pages (from-to)515-524
Number of pages10
JournalNuclear Medicine and Biology
Volume36
Issue number5
DOIs
StatePublished - Jul 2009

Fingerprint

Heterografts
Pharmacokinetics
Liposomes
Carcinoma, squamous cell of head and neck
liposomal doxorubicin
In Vitro Techniques
Nude Rats
Rhenium
Neoplasms
Liver
Head and Neck Neoplasms
Radioisotopes
Intravenous Administration
Doxorubicin
Biological Availability
Spleen
Kidney

Keywords

  • Biodistribution
  • Doxil
  • Liposome
  • Nanoparticle
  • Pharmacokinetics
  • Rhenium-186
  • SPECT/CT

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

[186Re]Liposomal doxorubicin (Doxil) : in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. / Soundararajan, Anuradha; Bao, Ande; Phillips, William T; Perez, Ricardo; Goins, Beth A.

In: Nuclear Medicine and Biology, Vol. 36, No. 5, 07.2009, p. 515-524.

Research output: Contribution to journalArticle

Soundararajan, Anuradha ; Bao, Ande ; Phillips, William T ; Perez, Ricardo ; Goins, Beth A. / [186Re]Liposomal doxorubicin (Doxil) : in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. In: Nuclear Medicine and Biology. 2009 ; Vol. 36, No. 5. pp. 515-524.
@article{02b2f89f29f941d189b22bba66f04f35,
title = "[186Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model",
abstract = "The purpose of this study was to determine the feasibility of radiolabeling liposomal doxorubicin (Doxil) for cancer chemoradionuclide therapy by directly loading the therapeutic radionuclide rhenium-186 (186Re) into the liposome interior. The pharmacokinetics, imaging and biodistribution of [186Re]Doxil (555 MBq/kg) and control [186Re]polyethylene glycol (PEG) liposomes (555 MBq/kg) were determined after intravenous administration in a head and neck cancer xenograft model in nude rats. [186Re]Doxil and [186Re]PEG liposomes were radiolabeled using [186Re]N,N-bis(2-mercaptoethyl)-N′,N′-diethylethylenediamine. 186Re labeling efficiency was 76.1±8.3{\%} with Doxil. The in vitro serum stability of [186Re]Doxil at 37°C was 38.06±12.13{\%} at 24 h. Pharmacokinetic studies revealed that [186Re]Doxil had a two-phase blood clearance with half clearance times of 0.8 and 28.2 h. Images acquired over 120 h showed that [186Re]Doxil had slow blood clearance, low liver accumulation and increasing spleen accumulation. The biodistribution study at 120 h indicated that the percentage of injected dose ({\%}ID) in the blood and tumor for [186Re]Doxil was 20-fold higher than that of [186Re]PEG liposomes. The {\%}ID values in the kidney and liver were not significantly different between [186Re]Doxil and [186Re]PEG liposomes. These results suggest that the long circulation and prolonged bioavailability of [186Re]Doxil could potentially deliver high concentrations of both doxorubicin and 186Re to tumor when encapsulated in the same liposome vehicle.",
keywords = "Biodistribution, Doxil, Liposome, Nanoparticle, Pharmacokinetics, Rhenium-186, SPECT/CT",
author = "Anuradha Soundararajan and Ande Bao and Phillips, {William T} and Ricardo Perez and Goins, {Beth A.}",
year = "2009",
month = "7",
doi = "10.1016/j.nucmedbio.2009.02.004",
language = "English (US)",
volume = "36",
pages = "515--524",
journal = "International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - [186Re]Liposomal doxorubicin (Doxil)

T2 - in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model

AU - Soundararajan, Anuradha

AU - Bao, Ande

AU - Phillips, William T

AU - Perez, Ricardo

AU - Goins, Beth A.

PY - 2009/7

Y1 - 2009/7

N2 - The purpose of this study was to determine the feasibility of radiolabeling liposomal doxorubicin (Doxil) for cancer chemoradionuclide therapy by directly loading the therapeutic radionuclide rhenium-186 (186Re) into the liposome interior. The pharmacokinetics, imaging and biodistribution of [186Re]Doxil (555 MBq/kg) and control [186Re]polyethylene glycol (PEG) liposomes (555 MBq/kg) were determined after intravenous administration in a head and neck cancer xenograft model in nude rats. [186Re]Doxil and [186Re]PEG liposomes were radiolabeled using [186Re]N,N-bis(2-mercaptoethyl)-N′,N′-diethylethylenediamine. 186Re labeling efficiency was 76.1±8.3% with Doxil. The in vitro serum stability of [186Re]Doxil at 37°C was 38.06±12.13% at 24 h. Pharmacokinetic studies revealed that [186Re]Doxil had a two-phase blood clearance with half clearance times of 0.8 and 28.2 h. Images acquired over 120 h showed that [186Re]Doxil had slow blood clearance, low liver accumulation and increasing spleen accumulation. The biodistribution study at 120 h indicated that the percentage of injected dose (%ID) in the blood and tumor for [186Re]Doxil was 20-fold higher than that of [186Re]PEG liposomes. The %ID values in the kidney and liver were not significantly different between [186Re]Doxil and [186Re]PEG liposomes. These results suggest that the long circulation and prolonged bioavailability of [186Re]Doxil could potentially deliver high concentrations of both doxorubicin and 186Re to tumor when encapsulated in the same liposome vehicle.

AB - The purpose of this study was to determine the feasibility of radiolabeling liposomal doxorubicin (Doxil) for cancer chemoradionuclide therapy by directly loading the therapeutic radionuclide rhenium-186 (186Re) into the liposome interior. The pharmacokinetics, imaging and biodistribution of [186Re]Doxil (555 MBq/kg) and control [186Re]polyethylene glycol (PEG) liposomes (555 MBq/kg) were determined after intravenous administration in a head and neck cancer xenograft model in nude rats. [186Re]Doxil and [186Re]PEG liposomes were radiolabeled using [186Re]N,N-bis(2-mercaptoethyl)-N′,N′-diethylethylenediamine. 186Re labeling efficiency was 76.1±8.3% with Doxil. The in vitro serum stability of [186Re]Doxil at 37°C was 38.06±12.13% at 24 h. Pharmacokinetic studies revealed that [186Re]Doxil had a two-phase blood clearance with half clearance times of 0.8 and 28.2 h. Images acquired over 120 h showed that [186Re]Doxil had slow blood clearance, low liver accumulation and increasing spleen accumulation. The biodistribution study at 120 h indicated that the percentage of injected dose (%ID) in the blood and tumor for [186Re]Doxil was 20-fold higher than that of [186Re]PEG liposomes. The %ID values in the kidney and liver were not significantly different between [186Re]Doxil and [186Re]PEG liposomes. These results suggest that the long circulation and prolonged bioavailability of [186Re]Doxil could potentially deliver high concentrations of both doxorubicin and 186Re to tumor when encapsulated in the same liposome vehicle.

KW - Biodistribution

KW - Doxil

KW - Liposome

KW - Nanoparticle

KW - Pharmacokinetics

KW - Rhenium-186

KW - SPECT/CT

UR - http://www.scopus.com/inward/record.url?scp=67349100518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349100518&partnerID=8YFLogxK

U2 - 10.1016/j.nucmedbio.2009.02.004

DO - 10.1016/j.nucmedbio.2009.02.004

M3 - Article

C2 - 19520292

AN - SCOPUS:67349100518

VL - 36

SP - 515

EP - 524

JO - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology

JF - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology

SN - 0969-8051

IS - 5

ER -